• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

某些新型异烟酸 2-(2-羟基-8-取代-三环[7.3.1.0(2.7)]十三碳-13-亚基)-酰肼的合成与生物活性

Synthesis and biological activities of some new isonicotinic acid 2-(2-hydroxy-8-substituted-tricyclo[7.3.1.0(2.7)]tridec-13-ylidene)-hydrazides.

作者信息

Matei Lilia, Bleotu Coralia, Baciu Ion, Diaconu Carmen Cristina, Hanganu Anamaria, Banu Otilia, Ionita Petre, Paun Anca, Tatibouët Arnaud, Zarafu Irina

机构信息

Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest, Romania; Faculty of Chemistry, University of Bucharest, Romania.

Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest, Romania.

出版信息

Bioorg Med Chem. 2015 Feb 1;23(3):401-10. doi: 10.1016/j.bmc.2014.12.038. Epub 2014 Dec 26.

DOI:10.1016/j.bmc.2014.12.038
PMID:25557899
Abstract

A series of several new isoniazid derivatives, isonicotinic acid 2-(2-hydroxy-8-substituted-tricyclo[7.3.1.0(2.7)]tridec-13-ylidene)-hydrazides, were synthesized and fully characterized. These new isoniazid derivatives were studied regarding their antibacterial activity and cytotoxicity, as well as their influences on some metabolizing enzymes. The best anti-mycobacterial activity was observed in the case of compounds containing alkyl side chains in the 8 position of tricyclo[7.3.1.0(2.7)]tridec-13-ylidene group. On contrary, the antimicrobial activity of these new compounds against various non-tuberculosis strains showed the best activity to be with the phenyl side chain of compound 6. It proved also to be the most toxic, inducing apoptosis and blocking the cell cycle in G0/G1 phase. The cell cycle was blocked in G0/G1 phase also by compound 3, but this compound did not show any toxicity. All compounds induced the expression of NAT1 and NAT2 genes in HT-29 cell line, and the expression of CYP1A1 in HT-29 and HCT-8 cell lines. The expression level of CYP3A4 was increased by compounds 1, 6 and 7 in HCT-8 cells. These results indicated that the activation of other metabolizing pathways, apart from those of isoniazid, take place. It might also point out the possibility of an increased isoniazid acetylation ratio by co-administration with new compounds in slow acetylators.

摘要

合成并全面表征了一系列几种新的异烟肼衍生物,即异烟酸2-(2-羟基-8-取代-三环[7.3.1.0(2.7)]十三碳-13-亚基)-酰肼。对这些新的异烟肼衍生物进行了抗菌活性、细胞毒性以及它们对某些代谢酶影响的研究。在三环[7.3.1.0(2.7)]十三碳-13-亚基基团的8位含有烷基侧链的化合物中观察到了最佳的抗分枝杆菌活性。相反,这些新化合物对各种非结核菌株的抗菌活性显示,化合物6的苯基侧链具有最佳活性。它也被证明是毒性最大的,可诱导细胞凋亡并使细胞周期阻滞在G0/G1期。化合物3也使细胞周期阻滞在G0/G1期,但该化合物没有显示出任何毒性。所有化合物均诱导HT-29细胞系中NAT1和NAT2基因的表达,以及HT-29和HCT-8细胞系中CYP1A1的表达。化合物1、6和7使HCT-8细胞中CYP3A4的表达水平升高。这些结果表明,除了异烟肼的代谢途径外,其他代谢途径也被激活。这也可能指出在慢乙酰化者中与新化合物共同给药时异烟肼乙酰化率增加的可能性。

相似文献

1
Synthesis and biological activities of some new isonicotinic acid 2-(2-hydroxy-8-substituted-tricyclo[7.3.1.0(2.7)]tridec-13-ylidene)-hydrazides.某些新型异烟酸 2-(2-羟基-8-取代-三环[7.3.1.0(2.7)]十三碳-13-亚基)-酰肼的合成与生物活性
Bioorg Med Chem. 2015 Feb 1;23(3):401-10. doi: 10.1016/j.bmc.2014.12.038. Epub 2014 Dec 26.
2
Synthesis and bioevaluation of some new isoniazid derivatives.合成及一些新异烟肼衍生物的生物评价。
Bioorg Med Chem. 2013 Sep 1;21(17):5355-61. doi: 10.1016/j.bmc.2013.06.013. Epub 2013 Jun 15.
3
Synthesis, Characterization, and Biologic Activity of New Acyl Hydrazides and 1,3,4-Oxadiazole Derivatives.新型酰基酰肼和 1,3,4-恶二唑衍生物的合成、表征和生物活性。
Molecules. 2020 Jul 21;25(14):3308. doi: 10.3390/molecules25143308.
4
Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.基于可再生脂肪酸的异烟肼衍生物的合成及抗分枝杆菌活性。
Bioorg Med Chem. 2013 Nov 15;21(22):6910-4. doi: 10.1016/j.bmc.2013.09.034. Epub 2013 Sep 20.
5
Synthesis of isonicotinoylhydrazones from anacardic acid and their in vitro activity against Mycobacterium smegmatis.从漆树酸合成异烟酰腙及其对耻垢分枝杆菌的体外活性。
Eur J Med Chem. 2007 Mar;42(3):420-4. doi: 10.1016/j.ejmech.2006.09.009. Epub 2006 Nov 15.
6
Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones.异烟酰腙的合成及其体内外抗分枝杆菌活性
Bioorg Med Chem Lett. 2005 Oct 15;15(20):4502-5. doi: 10.1016/j.bmcl.2005.07.011.
7
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.异烟酸酰肼类抗结核药物的作用方式及定量构效关系
J Med Chem. 1976 Apr;19(4):483-92. doi: 10.1021/jm00226a007.
8
Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.具有强效抗结核活性的新型异烟肼衍生物的设计、合成及生物学评价
Eur J Med Chem. 2014 Jun 23;81:119-38. doi: 10.1016/j.ejmech.2014.04.077. Epub 2014 Apr 29.
9
Fullerene isoniazid conjugate--a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity.富勒烯异烟肼共轭物——一种亲脂性增强的抗结核药:合成及抗分枝杆菌活性评价
Chem Biol Drug Des. 2009 May;73(5):553-7. doi: 10.1111/j.1747-0285.2009.00804.x.
10
Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.设计并合成双喹啉-异烟肼杂合体作为一类新型抗结核和抗菌药物。
Eur J Med Chem. 2013 Jul;65:348-59. doi: 10.1016/j.ejmech.2013.05.003. Epub 2013 May 14.

引用本文的文献

1
New Cobalt (II) Complexes with Imidazole Derivatives: Antimicrobial Efficiency against Planktonic and Adherent Microbes and In Vitro Cytotoxicity Features.新型钴(II)配合物与咪唑衍生物:对浮游和黏附微生物的抗菌效率和体外细胞毒性特征。
Molecules. 2020 Dec 24;26(1):55. doi: 10.3390/molecules26010055.
2
Synthesis, Characterization, and Biologic Activity of New Acyl Hydrazides and 1,3,4-Oxadiazole Derivatives.新型酰基酰肼和 1,3,4-恶二唑衍生物的合成、表征和生物活性。
Molecules. 2020 Jul 21;25(14):3308. doi: 10.3390/molecules25143308.
3
Synthesis and evaluation of new amidrazone-derived hydrazides as a potential anti-inflammatory agents.
新型脒腙衍生酰肼作为潜在抗炎剂的合成与评价
Monatsh Chem. 2018;149(8):1493-1500. doi: 10.1007/s00706-018-2197-8. Epub 2018 Jun 27.
4
Identification of KasA as the cellular target of an anti-tubercular scaffold.鉴定 KasA 为抗结核支架的细胞靶标。
Nat Commun. 2016 Sep 1;7:12581. doi: 10.1038/ncomms12581.